This study looked at a new approach for treating advanced neuroendocrine tumors (NETs) that start in places like the gut or lungs, not the pancreas. These are rare, slow-growing cancers where forming new blood vessels (angiogenesis) helps them survive. The trial tested whether adding a pill called axitinib, which blocks blood vessel growth, to the standard monthly hormone injection (octreotide) could help people live longer without their cancer getting worse.
256 patients who had already tried up to two other treatments were randomly assigned to get either axitinib plus the hormone shot, or a placebo pill plus the hormone shot. The main goal was to see if the axitinib group had longer progression-free survival (the time before the cancer started growing again). When doctors assessed the scans, the difference wasn't statistically clear. However, when a separate, blinded team of experts reviewed the scans, they found the axitinib group did have a longer period before growth—16.6 months versus 9.9 months. More people in the axitinib group also saw their tumors shrink significantly.
The trade-off was more side effects. Nearly a quarter of people on axitinib developed serious high blood pressure, and about 14% had serious diarrhea, though these were considered manageable. The study concluded that while the combination improved some outcomes, it did not meet its primary goal, and the benefit must be weighed against these added side effects.